You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
奧賽康(002755.SZ):擬5000萬元向揚州三藥增資
格隆匯 12-24 20:00

格隆匯12月24日丨奧賽康(002755.SZ)公佈,公司的子公司江蘇奧賽康藥業有限公司(“江蘇奧賽康”或“子公司”)擬以自有資金5000萬元向揚州市三藥製藥有限公司(“揚州三藥”)增資。

增資完成後,江蘇奧賽康將獲得揚州三藥20%股權。江蘇奧賽康與揚州三藥及其股東湯中信、湯俊、解家順、李玉江於2019年12月24日簽署了《投資協議書》。

公司及子公司專注於中國醫藥的主要細分市場,目前產品劑型主要定位於凍乾粉針製劑、固體口服制劑。藉助揚州三藥豐富的固體口服產品生產管理經驗,廠房及公共配套設施、完備的產業和技術工人,能夠快速高質量地打造子公司的固體口服在研產品的中試研發基地和固體口服制劑的產業化基地,來滿足子公司在研產品後續產業化的研發進度和產能需求。在保持凍乾粉針劑優勢的基礎上,進一步開展公司及子公司在固體口服制劑領域的產品佈局,滿足臨牀用藥需求增強企業競爭力,形成新的經濟增長點。

此次對外投資緊緊圍繞公司及子公司的主營業務展開,有效運行將對公司及子公司的長遠發展和企業效益將產生積極影響。投資資金來源為公司自有資金,不會對公司及子公司財務及經營狀況產生不利影響,不存在損害公司及全體股東利益的情形。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account